How telemedicine could help treat addiction

In a recent piece in The Palm Beach Post, reporter Christine Stapleton examined whether telemedicine can be used to treat recovering addicts.

Advertisement

The idea was a topic of discussion at the Addiction Industry Executive Summit in Naples, Fla., earlier this week.

Proponents believe using telemedicine could expand treatment access to addicts who live in rural areas or lack transportation. Psychologist Lisa Merconchini, PhD, founded Premier Telehealth, which uses copyrighted and encrypted software to protect patients. At the summit, Dr. Merconchini claimed she “was just surprised that treatment providers weren’t using this.”

However, opponents are wary telemedicine for addicts won’t give providers a full picture of the patient’s condition. “I have seen people trying to do it on a laptop or itty-bitty webcam,” Corey Waller, MD, senior medical director for education and policy at the Camden (N.J.) Coalition for Healthcare Providers, said at the conference. “If I can’t see [the] patient, I can’t see what’s going on. He could be flipping me off under the table.”

As the debate continues, psychiatrists and other providers must focus on the costs, licensing requirements and security obligations that come with utilizing telemedicine for addiction treatment.

More articles on telehealth:
Answer Health on Demand to teach physician assistant students about virtual care
VA researcher to connect rural veterans with HIV care
American Telemedicine Association releases 3 new guidelines

Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit

Advertisement

Next Up in Telehealth

Advertisement

Comments are closed.